POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Compared with the empty plasmid group and STAT3 low expression group, the mRNA and protein expression of markers of stem cells, OCT4, SOX2 and NANOG were significantly elevated in the STAT3 overexpression group with statistically significant differences (P<0.05), the formation ratio of tumor spheres in the STAT3 overexpression group was also significantly higher than those in the other two groups (P<0.05).
|
28781654 |
2017 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Hypoxia upregulates the core pluripotency factors NANOG, SOX2, and OCT4, associated with tumor aggressiveness and resistance to conventional anticancer treatments.
|
28093523 |
2017 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Based on the results of present study and published reports showing the presence of pluripotent markers (OCT-4, NANOG and SOX2) in human myometrial side population and expression of particularly OCT-4A in human leiomyomas, we speculate that these nuclear OCT-4 positive stem cells located in the perimetrium are the possible tumor initiating cells leading to the development of leiomyomas rather than the mesenchymal cells which express cytoplasmic OCT-4B.
|
28438190 |
2017 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Transcriptional master regulators like Sox2 and Oct4, which are expressed in various human tumors, have been shown to cause tumor growth promotion as well as epithelial dysplasia by means of interfering with progenitor cell differentiation.
|
28833847 |
2017 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The expression of the OCT4 protein was related to lymph node metastasis and TNM stage (p < 0.05), but not to gender, age and position of the tumor (p > 0.05).
|
29131256 |
2017 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
However the contribution of specific OCT4 isoforms to tumor aggressiveness is still poorly understood.
|
28186969 |
2017 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Considering the link between EMT and cancer stem cells, we show that PARP3 promotes stem-like cell properties in mammary epithelial and breast cancer cells by inducing the expression of the stem cell markers SOX2 and OCT4, by increasing the proportion of tumor initiating CD44high/CD24low population and the formation of tumor spheroid bodies, and by promoting stem cell self-renewal.
|
27579892 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Specifically, positive/high Oct-4 was associated with cancer stage III/IV (fixed effects: OR = 1.53, 95% CI = 1.12-2.10), primary tumor (T3-4) (random effects: OR = 1.93, 95% CI = 0.99-3.77), and cancer grade of differentiation (intermediate-poor) (random effects: OR = 3.45, 95% CI = 1.5-7.61).
|
26575328 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Overexpression of N-cadherin increased the efficiency of colony and tumor spheroid formation and the stemness factor expression (including c-Myc, Klf4, Sox2 and Oct4), and vice versa.
|
26647992 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
A single colony exhibited 42% occurrence of tumors with higher proliferation capacities. rG2-DC-1C showed continuous expression of the OCT4 stemness gene and of representative tumor markers, potentiated chemoresistance characteristics, and invasion activities.
|
27341307 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Higher OCT4 and SOX2 expressions were associated with earlier AJCC stage (P = 0.002 and P < 0.001), small tumor size (P = 0.017 and P = 0.001), and the absence of lymph node metastasis (P = 0.015 and P = 0.025).
|
26211876 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
All germinomas coexpressed Oct4 and Kit but showed an extensive global DNA demethylation compared to other tumors and normal tissues.
|
27391150 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Finally, we could also validate that Oct4 and Nanog are regulated by MACC1 in vitro and strongly correlate with MACC1 levels in a cohort of 60 tumors of colorectal cancer patients (r = 0.7005 and r = 0.6808, respectively; P > 0.0001 and P > 0.0002, respectively).
|
26758557 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Here, we found that expression levels of KPNA2 and OCT4 are up-regulated in bladder cancer tissues and significantly associated with primary tumor stage and bladder cancer patients' poorer prognosis.
|
27611951 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Furthermore, overexpression of Oct-4 enhanced tumor growth in the presence of tamoxifen in mice in vivo.
|
27065334 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Furthermore, Oct4-overexpressing PC9 cells (PC9-Oct4) significantly formed tumors at 1 × 10 cells/injection in NOG mice as compared to control cells.
|
26996130 |
2016 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Between Oct 4, 2012, and July 11, 2014, we screened 741 patients with any tumour type.
|
26342236 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Knock-down of miR-155 resulted in suppression of tumor sphere formation, through a decrease in the proportion of CD90(+) and CD133(+) CSCs and in the expression of Oct4, whereas miR-155 overexpression had the opposite effect.
|
25601564 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
However, at these stages, induced ubiquitous expression of Oct4 does not lead to restoration of pluripotency (indicated by Nanog expression) and tumour formation in utero, but instead causes a severe phenotype in the extending anteroposterior axis.
|
26453549 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Our findings suggest that Oct-3/4-expressing glioblastoma cells have the ability to adapt to low-oxygen environments within tumor masses by promoting tumor angiogenesis through AKT-HIF1 pathway.
|
25348671 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
OCT4 plays a critical role in the maintenance of stem cell pluripotency and proliferation, and is overexpressed in multiple human tumors, including endometrial cancer.
|
25634023 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Furthermore, compared with control cells, nestin short hairpin RNA (shRNA)-transfected glioblastoma cells exhibited reduced sphere formation, decreased expression of NANOG, N-cadherin, CD133, and Oct-4, and decreased tumor size in vivo.
|
25527454 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
This finding indicates that Oct4 or Nanog‑targeted therapy may be a promising means of overcoming resistance to chemotherapy and inhibiting tumor growth in breast cancer treatment.
|
25405855 |
2015 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Here we establish a sustainable primary culture of Oct3/4(+)/Nanog(+) lung CSCs fed with CD90(+) cancer-associated fibroblasts (CAFs) to further advance our knowledge of preserving stem cells in the tumour microenvironment.
|
24668028 |
2014 |
POU5F1P3
|
Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Our data revealed a significant coupregulation of SOX2OT along with SOX2 and OCT4 in tumor samples, compared to the non-tumor tissues obtained from the margin of same tumors.
|
24105929 |
2014 |